Sanofi
PARIS, I0 · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 5, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$629.9M2026 Q3
Positions16
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.92.1%
What Changed This Quarter?
Top Holdings
MGTX
MeiraGTx
21.3%
INBX
Inhibrx Biosciences
18.4%
NVAX
Novavax
11.8%
KRSA
Korsana Biosciences
10.1%
ODTX
Odyssey Therapeutics
7.0%
ANAB
Anaptysbio
6.6%
AGMB
AgomAb Therapeutics
4.9%
TRAX
First Tracks Biotherapeutics
4.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.